Patient Guide: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at 46 participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT05403450
Status: ACTIVE_NOT_RECRUITING
Condition: Relapsed/Refractory Peripheral T-cell Lymphoma
Phase: PHASE1, PHASE2

Find a Study Location Near You

This study is available at 46 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • • Duarte, California
  • • Los Angeles, California
  • • Stanford, California
  • • And 43 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) - Join Clinical Trial NCTNCT05403450

How to Join This Clinical Trial - NCTNCT05403450

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Relapsed/Refractory Peripheral T-cell Lymphoma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/Refractory Peripheral T-cell Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/Refractory Peripheral T-cell Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT05403450 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 46 locations. Find a study site near you:

Clinical Research Site

Duarte, California 91010 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90095 - United States

Status: Contact for availability

Clinical Research Site

Stanford, California 94305 - United States

Status: Contact for availability

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: Contact for availability

Clinical Research Site

New Haven, Connecticut 06511 - United States

Status: Contact for availability

Clinical Research Site

Tampa, Florida 33612 - United States

Status: Contact for availability

Clinical Research Site

Atlanta, Georgia 30322 - United States

Status: Contact for availability

Clinical Research Site

Baltimore, Maryland 21287 - United States

Status: Contact for availability

Clinical Research Site

Ann Arbor, Michigan 48109 - United States

Status: Contact for availability

Clinical Research Site

Detroit, Michigan 48201 - United States

Status: Contact for availability

And 36 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Relapsed/Refractory Peripheral T-cell Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

  • Find clinical trials that match your condition
  • Get matched to the right study location near you
  • Connect directly with study coordinators
  • Understand if you qualify with simplified eligibility screening
  • Navigate the enrollment process with personalized support
  • Access new treatments through clinical research participation